Extracellular Wound Matrices: Small intestinal submucosa wound matrix for chronic wound healing

Wounds

Volumn 19, Issue 6, 2007, Pages

  Hodde, Jason P ^a   Allam, Reynald ^b  

^a Cook Biotech Inc ^*  (United States)

^b Healthpoint Ltd   (United States)

Author keywords

Autolytic debridement; Compression stockings; Delayed wound healing; Diabetic foot wounds; Impaired wound healing; Mechanical debridement; Pressure dressing; Surgical debridement; Wound fibroblasts; Wound necrosis

Indexed keywords

EID: 34547359932     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Clark RA. Fibrin and wound healing. Ann NYAcad Sci. 2001;936:355-367.
2. Vande Berg JS, Robson MC. Arresting cell cycles and the effect on wound healing. Surg Clin North Am. 2003;83 (3):509-520.
3. Margolis DJ, Bilker W, Santanna J, Baumgarten M. Venous leg ulcer: incidence and prevalence in the elderly. J Am Acad Dermatol. 2002;46 (3):381-386.
4. Olin JW, Beusterien KM, Childs MB, Seavey C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vase Med. 1999;4(1):1-7.
5. Hareendran A, Bradbury A, Budd J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care. 2005;14(2):53-57.
6. Nabuurs-Franssen MH, Huijberts MS, Nieuwenhuijzen Kruseman AC, Willems J, Schaper NC. Health-related quality of life of diabetic foot ulcer patients and their caregivers. Diabetologia. 2005;48 (9):1906-1910.
7. Centers for Disease Control and Prevention. National diabetes surveillance system. Available at: http://www.cdc.gov/diabetes/statistics/prev/ national/figpersons.htm. Accessed February 6, 2007.
8. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(3):382-387.
9. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26 (6):1790-1795.
10. Wu S, Armstrong DG. Risk assessment of the diabetic foot and wound. Int Wound J. 2005;2 (1):17-24.
11. Amlung SR, Miller WL, Bosley LM. The 1999 National Pressure Ulcer Prevalence Survey: a benchmarking approach. Adv Skin Wound Care. 2001;14 (6):297-301.
12. National Pressure Ulcer Advisory Panel. Pressure ulcers in America: prevalence, incidence, and implications for the future. An executive summary of the National Pressure Ulcer Advisory Panel monograph. Adv Skin Wound Care. 2001;14 (4):208-215.
13. Beckrich K, Aronovitch SA. Hospital-acquired pressure ulcers: a comparison of costs in medical vs. surgical patients. Nurs Econ. 1999;17(5):263-271.
14. Redelings MD, Lee NE, Sorvillo F. Pressure ulcers: more lethal than we thought? Adv Skin Wound Care. 2005;18 (7):367-372.
15. Margolis DJ, AllenTaylor L, Hoffstad O, Berlin JA. Healing diabetic neuropathic foot ulcers: are we getting better? Diabet Med. 2005;22(2):172-176.
16. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002; 137 (7):822-827.
17. Franks PJ, Moffatt CJ. Health related quality of life in patients with venous ulceration: use of the Nottingham health profile. Qual Life Res. 2001;10(8):693-700.
18. Niezgoda JA, Van Gils CG, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18(5 Pt 1):258-266.
19. Demling RH, Niezgoda JA, Haraway GD, Mostow EN. Small intestinal submucosa wound matrix and fullthickness venous ulcers: preliminary results. WOUNDS. 2004;16(1):18-22.
20. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D; OASIS Venous Ulcer Study Group. Effectiveness of an extracellular matrix graft (Oasis Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vase Surg. 2005;41(5):837-843.
21. Vazquez JR, Short B, Findlow AH, Nixon BP, Boulton AJ, Armstrong DG. Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract. 2003;59 (2):123-127.
22. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebocontrolled doubleblind study. Diabetes Care. 1998;21 (5):822-827.
23. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22(5):692-695.
24. Solomon DE. An in vitro examination of an extracellular matrix scaffold for use in wound healing. Int J Exp Pathol. 2002;83 (5):209-216.
25. Hodde, J. Naturally-occurring scaffolds for soft tissue repair and regeneration. Tissue Eng. 2002;8(2):295-308.
26. Badylak SF. Small intestinal submucosa (SIS): a biomaterial conducive to smart tissue remodeling. In: Bell E, ed. Tissue Engineering: Current Perspectives. Cambridge, Mass: Burkhauser Publishers; 1993:179-189.
27. Hodde JP, Hiles MC. Virus safety of a porcine-derived medical device: evaluation of a viral inactivation method. Biotechnol Bioeng. 2002;79(2):211-216.
28. Kropp BP, Rippy MK, Badylak SF, et al. Regenerative urinary bladder augmentation using small intestinal submucosa: urodynamic and histopathologic assessment in long term canine bladder augmentations. J Urol. 1996;155(6):20982104.
29. Sandusky GE Jr, Badylak SF, Morff RJ, Johnson WD, Lantz G. Histologie findings after in vivo placement of small intestinal submucosal vascular grafts and saphenous vein grafts in the carotid artery in dogs. Am J Pathol. 1992;140(2):317-324.
30. McPherson TB, Badylak SF. Characterization of fibronectin derived from porcine small intestinal submucosa. Tissue Eng. 1998;4 (1):75-83.
31. Hodde JP, Badylak SF, Brightman AO, Voytik-Harbin SL. Glycosaminoglycan content of small intestinal submucosa: a bioscaffold for tissue replacement. Tissue Eng. 1996;2(3):209-217.
32. Hodde JP, Ernst DM, Hiles MC. An investigation of the long-term bioactivity of endogenous growth factor in Oasis Wound Matrix. J Wound Care. 2005;14(1):23-25.
33. McDevitt CA, Wildey GM, Cutrone RM. Transforming growth factor-b1 in a sterilized tissue derived from the pig small intestine submucosa. J Biomed Mater Res. 2003;67 (2):637-640.
34. Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care.2000;23(9):1333-1338.
35. Xue M, Le NT, Jackson CJ. Targeting matrix metalloproteases to improve cutaneous wound healing. Expert Opin Ther Targets. 2006;10(1):143-155.
36. Quatresooz P, Henry F, Paquet P, Pierard-Franchimont C, Harding K, Pierard GE. Deciphering the impaired cytokine cascades in chronic leg ulcers (review). Int J Mol Med. 2003;11 (4):411-418.
37. MacNeil S. What role does the extracellular matrix serve in skin grafting and wound healing? Burns. 1994;20(Suppl 1):S67-S70.
38. Hodde JP, Hiles MC. Bioactive FGF-2 in sterilized extracellular matrix. WOUNDS. 2001;13(5):195-201.
39. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):18791882.
40. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. Br J Dermatol. 2000;142(5):960-964.
41. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351(1):48-55.